NTRK3 Fusion

CI-VAR-00001209Explore in graph →CIViC 1277

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
v::NTRK3 Fusion	Entrectinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID2949 in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the a… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
v::NTRK3 Fusion	Larotrectinib	Predictive	B	Supports Sensitivity Response	2	submitted	EID2954 Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. PMID 26603524 · 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.